A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group trial, IND 129

Annals of Oncology

Volumn 14, Issue 4, 2003, Pages 543-548

  Gelmon, K A ^a   Vandenberg, T A ^b   Panasci, L ^c   Norris, B ^a   Crump, M ^d   Douglas, L ^e   Walsh, W ^f   Matthews, S J ^f   Seymour, L K ^f  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e ASTRAZENECA   (United Kingdom)

^f Queen's Cancer Research Institute   (Canada)

Author keywords

Breast cancer; Phase II studies; Platinum; ZD0473

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM(II); AMMINEDICHLORO(2-METHYLPYRIDINE)PLATINUM(II); PLATINUM COMPLEX;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; BREAST CANCER; CANADA; CANCER CENTER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COUGHING; DRY SKIN; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRANULOCYTOPENIA; HEADACHE; HEART PALPITATION; HUMAN; INFECTION; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; PETECHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; VISUAL IMPAIRMENT; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 0037481755     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg171     Document Type: Article

References (23)

1. Vermorken JB, Gundersen S, Smyth JF et al. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. Proc Am Soc Clin Oncol 1986; 5: 73 (Abstr 284).
2. Booth BW, Weiss RB, Korzun AH et al. Phase II trial of carboplatin in advanced breast carcinoma; a Cancer and Leukemia Group B study. Cancer Treat Rep 1985; 69: 919-920.
3. Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer-a phase II trial. Proc Am Soc Clin Oncol 1990; 9: 26 (Abstr 96).
4. Kolaric K, Roth A. Phase II clinical trial of cis-dichlordiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983; 11: 108-112.
5. Sledge GW, Loehrer PJ, Roth BJ et al. Cisplatin as first line therapy for metastatic breast cancer. J Clin Oncol 1988; 6: 1811-1814.
6. Smith IE, Talbot DC. Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br J Cancer 1992; 65: 787-793.
7. Pietras RJ, Fendly BM, Chazin VR et al. Antibody to HER-2/neu8 receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829-1838.
8. Pegram MD, Finn RS, Arzoo K et al. The effect of HER-2/neu over-expression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-547.
9. Pegram M, Hsu, S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-2251.
10. Pegram M, Lipton A, Hayes DF et al. Phase II study of receptor enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER 2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671.
11. Slamon DJ, Patel R, Northfelt R et al. Phase II pilot study of Herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2 neu proto-oncogene. A pilot study of the UCLA network. Proc Am Soc Clin Oncol 2001; 20: 49a (Abstr 193).
12. Nabholtz JM, Pienkowski T, Northfelt D et al. Results of two open label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (cis or carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumours overexpressing the HER2-neu proto-oncogene. Eur J Cancer 2001; 37: S190 (Abstr 695).
13. Holford J, Raynaud F, Murrer BA et al. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum coordination complex, cis-[amminedichloro (2-methylpyridine)] platinum (II) (AMD473). Anticancer Drug Des 1998; 13: 1-18.
14. Holford J, Sharp SY, Murrer BA et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex (AMD473). Br J Cancer 1998; 77: 366-373.
15. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-1542.
16. Kelland LR, Barnard CDJ. AMD 473. Drugs Fut 1998; 23: 1062-1065.
17. Medina-Gundrum L, Gomez L, Cerna C et al. ZD0473 exhibits marked in vitro anticancer activity in human tumor specimens. Proc Am Soc Clin Oncol 2001; 20: 439a (Abstr 1751).
18. Raynaud FI, Boxall FE, Goddard PM et al. Cis [aminedichlor (2-methylpyridine)] platinum (II) (AMD473) a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 1997; 3: 2063-2064.
19. Treat J, Huang C, Damanjov N et al. ZD0473 phase II monotherapy trial in second-line non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20: 264b (Abstr 2808).
20. Hoctin-Boes G, Cosaert J, Koehler M, Smith M. Safety profile of ZD0473 in phase II trials of patients with advanced cancers. Proc Am Soc Clin Oncol 2001; 20: 344a (Abstr 1372).
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 2000; 92: 205-216.
22. Fleming T. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
23. Gad S, Weil CS. Statistics and Experimental Design for Toxicologists. Caldwell, NJ: Telford Press 1981.